• Strong revenue growth from continuing operations (+191%) with best first half-year EBITDA since IPO
  • Cash position remains solid at EUR 77.5 million, key for further R&D development
  • Confirmed unique safety profile of Mithra’s innovative contraceptive pill Estelle® following positive results in both Europe/Russia and United States/Canada. Filing with regulatory authorities planned by end of 2019
  • Phase III E4 monotherapy study of Donesta® in menopause ready to start pending agency approvals
Liege, Belgium, 19 September 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces its financial results for the six-month period ending 30 June 2019, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.